Trial Profile

A Double-Blinded, Randomized, Placebo-Controlled, Proof of Concept Phase 2a Study Exploring the Safety and Efficacy of IMC-1 for the Treatment of Patients With Fibromyalgia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Celecoxib/famciclovir (Primary)
Indications Fibromyalgia; Myofascial pain
Focus Proof of concept; Therapeutic Use
Sponsors Dogwood Therapeutics; Innovative Med Concepts; Virios Therapeutics

Most Recent Events

30 Oct 2024 According to Virios Therapeutics media release, Virios Therapeutics has changed its name to Dogwood Therapeutics.
01 Mar 2024 According to a Virios Therapeutics media release, the company is looking forward to go ahead towards phase 3 with potential partners to fund the advancement.
26 Jul 2021 According to a Virios Therapeutics media release, FORTRESS trial builds on the encouraging results from this study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com